Trial Profile

Canakinumab long term effectiveness in pediatric and adult patients with Hereditary autoinflammatory diseases

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 02 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Canakinumab (Primary)
Indications Cryopyrin-associated periodic syndromes; Familial autosomal dominant periodic fever; Familial Mediterranean fever; Hereditary autoinflammatory diseases; Mevalonate Kinase Deficiency
Focus Adverse reactions; Therapeutic Use
Acronyms RELIANCE

15 Nov 2023 Interim results (n=101) assessing higher rates of disease control during the coronavirus pandemic in pediatric patients with autoinflammatory periodic diseases on canakinumab treatment presented at the ACR Convergence 2023
15 Nov 2023 Interim Results (n=232) assessing disease control between indications, parameters of 30 months visits presented at the ACR Convergence 2023
15 Nov 2023 Interim Results (n=232) assessing infections and infection rates presented at the ACR Convergence 2023

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com